Becton, Dickinson and Company (NYSE:BDX) Director Purchases $350,430.00 in Stock

Becton, Dickinson and Company (NYSE:BDX) Director Jeffrey William Henderson bought 1,500 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were purchased at an average cost of $233.62 per share, with a total value of $350,430.00. Following the acquisition, the director now directly owns 8,015 shares of the company’s stock, valued at approximately $1,872,464.30. This represents a 23.02 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Becton, Dickinson and Company Stock Down 1.7 %

Shares of NYSE BDX opened at $225.72 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99. The stock has a market capitalization of $65.46 billion, a P/E ratio of 37.50, a PEG ratio of 1.65 and a beta of 0.40. The stock’s fifty day moving average is $232.36 and its 200 day moving average is $233.94.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.84%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $283.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sound Income Strategies LLC grew its position in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the last quarter. Tompkins Financial Corp grew its position in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the last quarter. Birch Capital Management LLC grew its position in Becton, Dickinson and Company by 0.4% in the third quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock valued at $2,838,000 after acquiring an additional 48 shares during the last quarter. Radnor Capital Management LLC grew its position in Becton, Dickinson and Company by 1.7% in the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 48 shares during the last quarter. Finally, Wesbanco Bank Inc. grew its holdings in shares of Becton, Dickinson and Company by 1.9% during the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 48 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.